SUPERA Stenting in the Common Femoral Artery: Early Experience and Practical Considerations

Abstract

Purpose Endovascular therapy in the management of de novo common femoral disease remains controversial. Considerable interest has been generated in recent years due to recent technological advancement in the design of vascular stents. In particular, SUPERA (Abbot Vascular Inc, Santa Clara USA) stents are designed to offer increased flexibility and less adverse interactions with the arterial wall, thus making it potentially better suited for common femoral lesions. However, despite such theoretical advantages, there is lack of data in its use in clinical practice. This study provides illustrative examples of SUPERA stents in different clinical settings and contributes to important clinical data for the overall efficacy and safety profile of endovascular interventions in common femoral artery (CFA) disease. Materials and Methods Retrospective analysis of all endovascular CFA procedures between January 1, 2011, and December 31, 2019, was conducted. Data collected included demographics, clinical symptoms, medical comorbidities, procedural characteristics, and immediate and short-term complications. Detailed analysis was performed on the stenting cohort. Results During our study period, a total of 69 patients underwent endovascular interventions involving the CFA at our institution, of which 16 patients had stenting procedures for a total of 18 stent deployments. Technical success was achieved in all stenting procedures. A total of 15 SUPERA stents were placed in 13 patients. No stent fractures were observed. Overall primary patency rate of SUPERA stents at the time of 12-month follow-up was 100% in patients who had a follow-up assessment (n = 12 stents). Conclusion Endovascular intervention of the CFA is an evolving topic in the interventional radiology and vascular surgery community. Recent development of newer generation of devices such as SUPERA peripheral stents offers significant potential benefits given their inherent design. Despite the theoretically promising design of the SUPERA, there is a lack of data to support its use. This study contributes important patient-level data for SUPERA stent deployments.

Pure Endovascular versus Hybrid Approach for Management of Iliofemoral Arterial Disease: A Randomized Controlled Trial

“…These findings were inconsistent to study conducted by Tao et al, who reported mean PSVR presenting 3.74 AE 7.11 versus 1.12 AE 0.56; however, this difference was not statistically significant (p ¼ 0.11). 5 In the present study, 32 (88.9%) patients reported improvement of the clinical symptoms, 28 (87.5%) patients had intact pulse postoperatively, and 28 (87.5%) had patent vessels. Follow-up showed that none developed reclusion or restenosis during the period of follow-up.…”

“…These findings were consistent with Toa et al and Gouëffic et al, who reported noninferiority of endovascular tech-nique versus hybrid and open angioplasty techniques in terms of clinical improvement, patency, and intact pulse postoperatively. 5,7 In the current study we did not report any major complications regarding cardiovascular events, cerebrovascular events, stent fracture, 30-day mortality, and morbidity. These findings are better than that reported by several studies investigating the endovascular management of CFA.…”

“…These findings were inconsistent to study conducted by Tao et al, who reported mean PSVR presenting 3.74 ± 7.11 versus 1.12 ± 0.56; however, this difference was not statistically significant ( p = 0.11). 5…”

“…These findings were consistent with the recent study conducted by Tao et al, who stated that 9/13 patients who underwent SUPERA stent insertion had reported clinical improvement, while 1 patient reported no improvement of symptoms and 3 patients worsened. 5…”

“…These findings were consistent with Toa et al and Gouëffic et al, who reported noninferiority of endovascular technique versus hybrid and open angioplasty techniques in terms of clinical improvement, patency, and intact pulse postoperatively. 5 7…”